Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

ASCO 2024

31 May - 4 Jun 2024

Published: 2 Jun 2024

Views: 44

Rating:

Save

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Prof Karim Fizazi speaks to ecancer at ASCO 2024 about a study looking at health-related quality of life and pain with the use of lutetium-177–PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer .

He explains that patients were randomized 1:1 to open-label lutetium-177–PSMA-617 or ARPI change (abiraterone/enzalutamide).

Prof Fizazi reports that self-reported data collected from two questionnaires showed that lutetium-177–PSMA-617 improved time to deterioration in quality of life by approximately 40%.

Related Videos

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of...

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Digital rectal examination is not useful as a solitary screening tool for...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

Single intensive screening intervention using PSA and Stockholm3 in combination...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Single intensive screening intervention using PSA and Stockholm3 in combination might reduce prostate cancer mortality ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer